Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25995242 | 0.98 | IGF1R (0.48) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25995232 | 0.98 | IGF1R (0.48) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25995244 | 0.98 | IGF1R (0.48) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25995258 | 0.98 | IGF1R (0.48) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25995219 | 0.98 | IGF1R (0.48) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25995153 | 0.95 | IGF1R (0.47) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25998034 | 0.91 | IGF1R (0.42) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25998369 | 0.90 | IGF1R (0.41) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25998242 | 0.90 | IGF1R (0.41) | IGF1RALOX15BACE1CDK1ALOX5 | |
| SCHEMBL25998378 | 0.90 | IGF1R (0.41) | IGF1RALOX15BACE1CDK1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | IGF1R 211/4885ALOX15 307/4885BACE1 4709/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | IGF1R 115/4885ALOX15 325/4885BACE1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.